Nuplazid was Acadia Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $680.09M of $1.07B (63%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Nuplazid | $517.24M | $549.25M | $609.39M | $680.09M |
| Daybue | — | $177.19M | $348.41M | $391.42M |
| Total | $517.24M | $726.44M | $957.80M | $1.07B |
Acadia Pharmaceuticals brought in $1.07B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 11.9% from $957.80M in fiscal 2024. Nuplazid was the largest at $680.09M (63.5%), ahead of Daybue at $391.42M (36.5%).
Compared with fiscal 2024, Daybue grew 12.3% to $391.42M and Nuplazid grew 11.6% to $680.09M.
Acadia Pharmaceuticals began breaking out Daybue in fiscal 2023, when it brought in $177.19M.
Nuplazid was Acadia Pharmaceuticals’s largest revenue line in fiscal 2025, bringing in $680.09M of $1.07B (63%).
| Customer | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Nuplazid | $517.24M | $549.25M | $609.39M | $680.09M | |
| Daybue | — | $177.19M | $348.41M | $391.42M | |
| Total | $517.24M | $726.44M | $957.80M | $1.07B |
Acadia Pharmaceuticals brought in $1.07B from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 11.9% from $957.80M in fiscal 2024. Nuplazid was the largest at $680.09M (63.5%), ahead of Daybue at $391.42M (36.5%).
Compared with fiscal 2024, Daybue grew 12.3% to $391.42M and Nuplazid grew 11.6% to $680.09M.
Acadia Pharmaceuticals began breaking out Daybue in fiscal 2023, when it brought in $177.19M.
Acadia Pharmaceuticals (ACAD) reports its revenue by product and service and by customer. In fiscal 2025, Nuplazid was its largest product and service line, bringing in $680.09M (63.5% of the total), followed by Daybue at $391.42M (36.5%).
Nuplazid was Acadia Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $680.09M, or 63.5% of the $1.07B total across its two product and service lines.
Nuplazid was Acadia Pharmaceuticals' largest revenue line in fiscal 2025, bringing in $680.09M, or 63.5% of the $1.07B total across its two revenue lines.
Daybue grew faster than Nuplazid in fiscal 2025, up 12.3% from $348.41M to $391.42M. Nuplazid grew 11.6% to $680.09M.
Every figure comes from Acadia Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Acadia Pharmaceuticals gives it, and years follow its fiscal calendar.
Acadia Pharmaceuticals' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.